Updating results

Acute coronary syndromes

In development [GID-NG10085] Expected publication date: 30 July 2020

NICE guideline In development

Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

In development [GID-TA10545] Expected publication date: 19 September 2020

Technology appraisal guidance In development

Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

In development [GID-TA10567] Expected publication date: 24 November 2021

Technology appraisal guidance In development

Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

In development [GID-TA10387] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

In development [GID-TA10590] Expected publication date: 19 May 2021

Technology appraisal guidance In development

Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis

In development [GID-IPG10117] Expected publication date: 20 May 2020

Interventional procedures guidance In development

Balloon cryoablation for Barrett's oesophagus

In development [GID-IPG10127] Expected publication date: 17 June 2020

Interventional procedures guidance In development

Balloon cryoablation for squamous dysplasia of the oesophagus

In development [GID-IPG10139] Expected publication date: 17 June 2020

Interventional procedures guidance In development

The MAGEC system for spinal lengthening in children with scoliosis

In development [GID-MT544] Expected publication date: 15 September 2020

Medical technologies guidance In development

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498

In development [GID-TA10420] Expected publication date: 23 June 2021

Technology appraisal guidance In development

Axonics sacral neuromodulation system for bladder control in people with symptoms of overactive bladder

In development [GID-MT530] Expected publication date: 01 June 2020

Medical technologies guidance In development

Liraglutide for managing overweight and obesity [ID740]

In development [GID-TA10388] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Peezy Midstream for urine collection

In development [GID-MT538] Expected publication date: 26 January 2021

Medical technologies guidance In development

Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: 13 January 2021

Highly specialised technologies guidance In development

Multiple sclerosis in adults: management

In development [GID-NG10153] Expected publication date: 04 May 2022

NICE guideline In development

Inducing labour (update)

In development [GID-NG10082] Expected publication date: TBC

NICE guideline In development

Laser lithotripsy for difficult-to-treat bile duct stones

In development [GID-IPG10157] Expected publication date: TBC

Interventional procedures guidance In development

Perioperative care in adults

In development [GID-NG10072] Expected publication date: 27 May 2020

NICE guideline In development

Radiofrequency ablation for palliation of painful spinal metastases

In development [GID-IPG10158] Expected publication date: TBC

Interventional procedures guidance In development

Bilateral cervicosacropexy or vaginosacropexy using mesh for pelvic organ prolapse

In development [GID-IPG10123] Expected publication date: 04 March 2020

Interventional procedures guidance In development

Artificial iris insertion for acquired aniridia

In development [GID-IPG10130] Expected publication date: 22 April 2020

Interventional procedures guidance In development

Artificial iris insertion for congenital aniridia

In development [GID-IPG10144] Expected publication date: 22 April 2020

Interventional procedures guidance In development

Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

In development [GID-DG10023] Expected publication date: 27 May 2020

Diagnostics guidance In development

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

In development [GID-TA10582] Expected publication date: TBC

Technology appraisal guidance In development

Caesarean section (update)

In development [GID-NG10081] Expected publication date: 21 January 2021

NICE guideline In development

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [ID1402]

In development [GID-TA10328] Expected publication date: TBC

Technology appraisal guidance In development

Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer [ID1443]

In development [GID-TA10476] Expected publication date: 25 November 2020

Technology appraisal guidance In development

Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [ID1516]

In development [GID-TA10468] Expected publication date: 10 June 2020

Technology appraisal guidance In development

Workplace health: long-term sickness absence and capability to work

In development [GID-QS10114] Expected publication date: 13 January 2021

Quality standard In development

Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer ID1495

In development [GID-TA10395] Expected publication date: TBC

Technology appraisal guidance In development

Pelvic floor dysfunction: prevention and non-surgical management

In development [GID-NG10123] Expected publication date: 26 August 2021

NICE guideline In development

Tobacco: preventing uptake, promoting quitting and treating dependence (update)

In development [GID-NG10086] Expected publication date: 18 January 2021

NICE guideline In development

Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

In development [GID-TA10616] Expected publication date: TBC

Technology appraisal guidance In development

Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

In development [GID-IP2806] Expected publication date: TBC

Interventional procedures guidance In development

Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

In development [GID-TA10234] Expected publication date: TBC

Technology appraisal guidance In development

Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

In development [GID-TA10252] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

In development [GID-TA10472] Expected publication date: TBC

Technology appraisal guidance In development

IMCgp100 for treating metastatic uveal melanoma (ID1441)

In development [GID-TA10428] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335

In development [GID-TA10315] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

In development [GID-TA10474] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

In development [GID-TA10473] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

In development [GID-TA10223] Expected publication date: TBC

Technology appraisal guidance In development

Maternal health

In development [GID-QS10077] Expected publication date: TBC

Quality standard In development

Eculizumab for treating refractory myasthenia gravis [ID1064]

In development [GID-TA10176] Expected publication date: TBC

Technology appraisal guidance In development

Cutting blocks for total knee arthroplasty

In development [GID-IP1112] Expected publication date: TBC

Interventional procedures guidance In development

School-based interventions: physical and mental health and wellbeing promotion

In development [GID-QS10070] Expected publication date: TBC

Quality standard In development

Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

In development [GID-TA10465] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]

In development [GID-TA10449] Expected publication date: TBC

Technology appraisal guidance In development